Antibody therapeutics that bind CD123
There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
1. A fully human anti-CD123 antibody, or an antigen binding fragment thereof, that binds to a CD123 epitope, said anti-CD123 antibody or antigen-binding fragment thereof comprising:
a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO. 19 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO. 20.
2. The fully human anti-CD123 antibody, or antigen binding fragment thereof, of claim 1 , wherein the anti-CD123 antibody or antigen binding fragment thereof binds to the CD123 epitope with a dissociation constant (K D ) of at least 1×10 −6 M.
3. The fully human anti-CD123 antibody of claim 1 , wherein the antibody is an IgG.
4. The fully human anti-CD123 antibody of claim 3 , wherein the antibody is an IgG1 or an IgG4.
5. The fully human anti-CD123 antibody, or antigen-binding fragment thereof, of claim 1 , wherein the anti-CD123 antibody, or antigen-binding fragment thereof, is selected from the group consisting of a Fab, a Fab′, a F(ab′)2, an Fv, a single chain antibody, a chimeric antibody, a diabody, a triabody, and a tetrabody.
6. The fully human anti-CD123 antibody, or antigen-binding fragment thereof, of claim 5 , wherein said single chain antibody comprises:
a heavy chain variable domain region;
a light chain variable domain region;
a peptide linker connecting the heavy chain variable domain region and light chain variable domain region;
wherein the heavy chain variable domain region comprises the amino acid sequence of SEQ ID NO. 19 and the light chain variable domain region comprises the amino acid sequence of SEQ ID NO. 20.
7. A method for treating a CD123 positive cancer in a human subject in need thereof, the method comprising:
administering an effective amount of a fully human anti-CD123 antibody, or an antigen binding fragment thereof, that binds to a CD123 epitope, said anti-CD123 antibody or antigen-binding fragment thereof comprising:
a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO. 19 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO. 20.
8. The method of claim 7 , wherein the anti-CD123 antibody or antigen binding fragment thereof binds to the CD123 epitope with a dissociation constant (K D ) of at least 1×10 −6 M.
9. The method of claim 7 , wherein the antibody is an IgG.
10. The method of claim 9 , wherein the antibody is an IgG1 or an IgG4.
11. The method of claim 7 , wherein the anti-CD123 antibody, or antigen-binding fragment thereof, is selected from the group consisting of a Fab, a Fab′, a F(ab′)2, an Fv, a single chain antibody, a chimeric antibody, a diabody, a triabody, and a tetrabody.
12. The method of claim 11 , wherein said single chain antibody comprises:
a heavy chain variable domain region;
a light chain variable domain region; and
a peptide linker connecting the heavy chain variable domain region and light chain variable domain region;
wherein the heavy chain variable domain region comprises the amino acid sequence of SEQ ID NO. 19 and the light chain variable domain region comprises the amino acid sequence of SEQ ID NO. 20.
13. The method of claim 7 , wherein the cancer is selected from the group consisting of non-Hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, B chronic lymphocytic leukemia, B and T acute lymphocytic leukemia, T cell lymphoma, acute myeloid leukemia, hairy cell leukemia, Hodgkin's Lymphoma, and chronic myeloid leukemia.
14. A pharmaceutical composition comprising the fully human anti-CD123 antibody, or antigen-binding fragment thereof, of claim 1 , and a pharmaceutically acceptable carrier.